tirzepatide litigation FDA's decision creates uncertainty for patients—and leads to a lawsuit Lilly, Novo Fight Weight Loss

This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 189,00 per year only 15,75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

The study suggested that liraglutide, another GLP-1 receptor agonist, prevented depressive-like behavior induced by pentylenetetrazol

If youre ready for a practical next step, see if you qualify for a personalized program

But there's another important timeline to consider: the beyond-use date

Its been almost a month and the side effects have been very limited and easy to deal with

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse